Celgene reports 4Q17 earns, expresses interest in M&A

Celgene Corp. (NASDAQ:CELG) reported fourth quarter earnings Thursday, including EPS that topped the Street's estimates, driven by U.S. sales of cancer drug Revlimid lenalidomide. On the heels of two acquisition deals this month, Celgene also said it is open to more M&A, if the

Read the full 440 word article

User Sign In